2023 연구성과 (21 / 285)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| WoS | SCOPUS | Document Type | Document Title | Abstract | Authors | Affiliation | ResearcherID (WoS) | AuthorsID (SCOPUS) | Author Email(s) | Journal Name | JCR Abbreviation | ISSN | eISSN | Volume | Issue | WoS Edition | WoS Category | JCR Year | IF | JCR (%) | FWCI | FWCI Update Date | WoS Citation | SCOPUS Citation | Keywords (WoS) | KeywordsPlus (WoS) | Keywords (SCOPUS) | KeywordsPlus (SCOPUS) | Language | Publication Stage | Publication Year | Publication Date | DOI | JCR Link | DOI Link | WOS Link | SCOPUS Link |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ○ | ○ | Article | Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer: Secondary Analysis of a Randomized Clinical Trial | IMPORTANCE Trastuzumab has been the standard of care for the treatment of patients with ERBB2-positive breast cancer; however, cardiac events have been reported. This long-term follow-up study provides clinical evidence supporting the similarity of a trastuzumab biosimilar (SB3) to reference trastuzumab (TRZ). OBJECTIVE To compare cardiac safety and efficacy between SB3 and TRZ for patients with ERBB2-positive early or locally advanced breast cancer after up to 6 years of follow-up. DESIGN, SETTING, AND PARTICIPANTS This prespecified secondary analysis of a randomized clinical trial, conducted from April 2016 to January 2021, included patients with ERBB2-positive early or locally advanced breast cancer from a multicenter double-blind, parallel-group, equivalence phase 3 randomized clinical trial of SB3 vs TRZ with concomitant neoadjuvant chemotherapy who completed neoadjuvant and adjuvant treatment. INTERVENTIONS In the original trial, patients were randomized to either SB3 or TRZ with concomitant neoadjuvant chemotherapy for 8 cycles (4 cycles of docetaxel followed by 4 cycles of fluorouracil, epirubicin, and cyclophosphamide). After surgery, patients continued SB3 or TRZ monotherapy for 10 cycles of adjuvant treatment per previous treatment allocation. Following neoadjuvant and adjuvant treatment, patients were monitored for up to 5 years. MAIN OUTCOMES AND MEASURES The primary outcomes were the incidence of symptomatic congestive heart failure and asymptomatic, significant decrease in left ventricular ejection fraction (LVEF). The secondary outcomes were event-free survival (EFS) and overall survival (OS). RESULTS A total of 538 female patients were included (median age, 51 years [range, 22-65 years]). Baseline characteristics were comparable between the SB3 and TRZ groups. Cardiac safety was monitored for 367 patients (SB3, n=186; TRZ, n=181). Median follow-up was 68 months (range, 8.5-78.1 months). Asymptomatic, clinically significant LVEF decreases were rarely reported (SB3, 1 patient [0.4%]; TRZ, 2 [0.7%]). No patient experienced symptomatic cardiac failure or death due to a cardiovascular event. Survival was evaluated for the 367 patients in the cardiac safety cohort and an additional 171 patients enrolled after a protocol amendment (538 patients [SB3, n=267; TRZ, n=271]). No difference was observed in EFS or OS between treatment groups (EFS: hazard ratio [HR], 0.84; 95% CI, 0.58-1.20; P=.34; OS: HR, 0.61; 95% CI, 0.36-1.05; P=.07). Five-year EFS rates were 79.8% (95% CI, 74.8%-84.9%) in the SB3 group and 75.0% (95% CI, 69.7%-80.3%) in the TRZ group, and OS rates were 92.5% (95% CI, 89.2%-95.7%) in the SB3 group and 85.4% (95% CI, 81.0%-89.7%) in the TRZ group. CONCLUSIONS AND RELEVANCE In this secondary analysis of a randomized clinical trial, SB3 demonstrated cardiac safety and survival comparable to those of TRZ after up to 6 years of follow-up in patients with ERBB2-positive early or locally advanced breast cancer. | Pivot, Xavier; Cortes, Javier; Lueftner, Diana; Lyman, Gary H.; Curigliano, Giuseppe; Bondarenko, Igor M.; Ahn, Jin-Hee; Im, Seock-Ah; Litwiniuk, Maria; Shparyk, Yaroslav V.; Ho, Gwo Fuang; Kislov, Nikolay V.; Wojtukiewicz, Marek; Sarosiek, Tomasz; Chae, Yee Soo; Ahn, Jin Seok; Jang, Hyerin; Kim, Sujung; Lee, Jiwon; Yoon, YeChan | Inst Cancerol Strasbourg Europe, Strasbourg, France; Quironsalud Grp, Int Breast Canc Ctr, Pangaea Oncol, Barcelona, Spain; Med Scientia Innovat Res, Dept Sci, Valencia, Spain; Univ Europea Madrid, Fac Biomed & Hlth Sci, Dept Med, Madrid, Spain; Immanuel Hosp Mark Schweiz, Campus Rudersdorf, Rudersdorf Bei Berlin, Germany; Med Univ Brandenburg Theodor Fontane, Campus Rudersdorf, Rudersdorf Bei Berlin, Germany; Fred Hutchinson Canc Res Ctr, Seattle, WA USA; Univ Milan, European Inst Oncol, IRCCS, Milan, Italy; Dnipropetrovsk City Multi Field Clin Hosp 4, Dnepropetrovsk, Ukraine; Asan Med Ctr, Seoul, South Korea; Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Canc Res Inst, Seoul, South Korea; Greater Poland Canc Ctr, Poznan, Poland; Poznan Univ Med Sci, Poznan, Poland; Lviv State Oncol Reg Therapeut & Diagnost Ctr, Lvov, Ukraine; Univ Malaya, Med Ctr, Kuala Lumpur, Malaysia; State Budgetary Healthcare Inst Yaroslavl Region, Reg Clin Oncol Hosp, Yaroslavl, Russia; Bialostockie Cent Onkol Marii Sklodowskiej, Bialystok, Poland; LUX MED Onkol, Warsaw, Poland; Kyungpook Natl Univ, Chilgok Hosp, Daegu, South Korea; Samsung Med Ctr, Seoul, South Korea; Samsung Bioepis, Incheon, South Korea | HO, GWO FUANG/B-8634-2010; Ahn, Jin/C-6122-2019; Lyman, Gary/K-5227-2019; CORTES CASTAN, JAVIER/ADX-3837-2022; Curigliano, Giuseppe/D-3371-2018; Im, Seock-Ah/J-5620-2012; Bondarenko, Igor/U-5156-2017 | 7003612474; 7201403402; 7003401023; 7005796039; 57221578995; 24729417400; 7403019217; 34570185300; 8245501500; 23500008900; 55009123200; 25951475100; 7005978177; 16833917200; 57190793908; 56525813200; 58172365400; 57204536456; 58172510700; 57210557462 | x.pivot@icans.eu; | JAMA NETWORK OPEN | JAMA NETW OPEN | 2574-3805 | 6 | 4 | SCIE | MEDICINE, GENERAL & INTERNAL | 2023 | 10.5 | 3.5 | 2.05 | 2025-06-25 | 8 | 8 | ADJUVANT TRASTUZUMAB; FOLLOW-UP; PHASE-III; NEOADJUVANT; SURVIVAL; EVENTS; POLYMORPHISMS; CHEMOTHERAPY; ASSOCIATION; EPIRUBICIN | Biosimilar Pharmaceuticals; Breast Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Receptor, ErbB-2; Stroke Volume; Trastuzumab; Ventricular Function, Left; cyclophosphamide; docetaxel; epirubicin; fluorouracil; trastuzumab; biosimilar agent; epidermal growth factor receptor 2; ERBB2 protein, human; trastuzumab; adult; advanced breast cancer; aged; Article; asymptomatic disease; cancer adjuvant therapy; cancer staging; cancer surgery; cancer survival; cohort analysis; comparative effectiveness; congestive heart failure; controlled study; drug efficacy; drug safety; early cancer; ECOG Performance Status; event free survival; female; follow up; heart left ventricle ejection fraction; heart muscle fibrosis; human; human epidermal growth factor receptor 2 positive breast cancer; incidence; invasive ductal carcinoma; invasive lobular breast carcinoma; long term survival; major clinical study; middle aged; minimal residual disease; monotherapy; neoadjuvant chemotherapy; outcome assessment; overall survival; patient monitoring; postoperative care; randomized controlled trial (topic); secondary analysis; treatment outcome; treatment response; young adult; breast tumor; clinical trial; heart left ventricle function; heart stroke volume; multicenter study; phase 3 clinical trial; randomized controlled trial | English | 2023 | 2023-04 | 10.1001/jamanetworkopen.2023.5822 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||||
| ○ | Meeting Abstract | Computational fluid dynamics analysis of computed tomography images in asthma | Kim, So Ri; Nguyen Quoc Hung; Chae, Kum Ju; Jin, Gong Yong; Choi, Sanghun | Jeonbuk Natl Univ, Med Sch, Jeonju, South Korea; Kyungpook Natl Univ, Daegu, South Korea | Hùng, Nguyễn Quốc/ADB-5196-2022; Kim, So/AAS-1630-2021; Kim, Jong/J-2749-2012; Choi, Sanghun/AGS-7430-2022 | sori@jbnu.ac.kr; | EUROPEAN RESPIRATORY JOURNAL | EUR RESPIR J | 0903-1936 | 1399-3003 | 62 | SCIE | RESPIRATORY SYSTEM | 2023 | 17 | 3.5 | 0 | English | 2023 | 2023-09-09 | 10.1183/13993003.congress-2023.pa2287 | 바로가기 | 바로가기 | 바로가기 | |||||||||||||
| ○ | Meeting Abstract | CyTOF analysis for differential immune cellular profiling between latent tuberculosis infection and active tuberculosis | Park, Ji Eun; Lee, Jaehee | Kyungpook Natl Univ, Sch Med, Daegu, South Korea | Lee, Yoojin/AAB-9799-2022 | jieun@knu.ac.kr; | EUROPEAN RESPIRATORY JOURNAL | EUR RESPIR J | 0903-1936 | 1399-3003 | 62 | SCIE | RESPIRATORY SYSTEM | 2023 | 17 | 3.5 | 0 | English | 2023 | 2023-09-09 | 10.1183/13993003.congress-2023.pa1060 | 바로가기 | 바로가기 | 바로가기 | |||||||||||||
| ○ | ○ | Article | Existence and nonexistence of traveling waves of coupled Burgers' equations | Traveling waves of a system of viscous coupled Burgers' equations are classified in this paper. Traveling wave solutions of the scalar Burgers' equation are simple, exhibiting a step-down or step-up wave pattern. Conversely, numerous different wave patterns can appear for the coupled Burgers' system; these wave patterns are determined by the strength of the coupling constants and other parameters. Comprehension of the solutions of these traveling waves needs to precede the study of various other aspects of the system, such as the stability of numerical schemes. We point out that those rich interacting patterns observed in this study provide an important class of special solutions that deserve tests over various numerical schemes, in particular to suppress spurious oscillations that have been reported in the literature. It turns out that eight different parameter regimes account for the entire system with relevant parameters. For each of the eight regimes, we completely characterize the existence and nonexistence of traveling waves within a class that we introduced in the study. We observed left-moving and right-moving waves involving a variety of wave patterns. Waves of crossing patterns, where one species steps up and the other steps down, and bump-like patterns were shown to exist. We also provided numerical results for a selected set of traveling waves to illustrate the established results of existence and nonexistence.& COPY; 2023 Elsevier B.V. All rights reserved. | Jeong, Chanwoo; Kim, Philsu; Lee, Min -Gi | Kyungpook Natl Univ, Dept Math, Daegu, South Korea | 58477398900; 7402334786; 36704125500 | jeongcw.mail@gmail.com;kimps@knu.ac.kr;leem@knu.ac.kr; | COMMUNICATIONS IN NONLINEAR SCIENCE AND NUMERICAL SIMULATION | COMMUN NONLINEAR SCI | 1007-5704 | 1878-7274 | 125 | SCIE | MATHEMATICS, APPLIED;MATHEMATICS, INTERDISCIPLINARY APPLICATIONS;MECHANICS;PHYSICS, FLUIDS & PLASMAS;PHYSICS, MATHEMATICAL | 2023 | 3.4 | 3.5 | 0.19 | 2025-06-25 | 1 | 1 | Coupled Burgers' equation; Traveling wave solutions; Global analysis; Existence and nonexistence | DILUTE POLYDISPERSE SYSTEM; LATTICE BOLTZMANN MODEL; COLLOCATION METHOD; NUMERICAL-SIMULATION; INTERACTING SPHERES; SEDIMENTATION | Coupled Burgers’ equation; Existence and nonexistence; Global analysis; Traveling wave solutions | Burger's equations; Classifieds; Coupled burger's equations; Existence and non existences; Global analysis; Simple++; Step down; Traveling wave solution; Travelling waves; Wave patterns | English | 2023 | 2023-10 | 10.1016/j.cnsns.2023.107385 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |||
| ○ | ○ | Article | Myriocin suppresses tumor growth by modulating macrophage polarization and function through the PI3K/Akt/mTOR pathway | Macrophages within the tumor microenvironment (TME), referred to as tumor-associated macrophages (TAMs), are involved in various aspects of tumor progression including initiation, angiogenesis, metastasis, immunosuppression, and resistance to therapy. Myriocin, a natural compound isolated from Mycelia sterilia, is an immunosuppressant that inhibits tumor growth and angiogenesis. However, the mechanisms underlying the effects of myriocin on TAMs and TAM-mediated tumor growth have not yet been elucidated. In this study, we determined the effects of myriocin on TAMs and the underlying mechanism in vitro and in vivo. Myriocin significantly suppressed monocyte-macrophage differentiation and M2 polarization of macrophages but not M1 polarization. In addition, myriocin inhibited the expression of anti-inflammatory cytokines and secretion of proangiogenic factors, such as vascular endothelial growth factor, in M2 macrophages as well as M2-induced endothelial cell permeability. Myriocin also inhibited the PI3K/Akt/mTOR signaling pathway in M2 macrophages. Myriocin reduced the population of M2-like TAMs within the tumor tissue of a mouse allograft tumor model but not that of M1-like TAMs. Moreover, combined treatment with myriocin and cisplatin synergistically suppressed tumor growth and enhanced survival rate in mice by reducing the population of M2-like TAMs. Overall, these results suggest that myriocin inhibits tumor growth by remodeling the TME through suppression of differentiation and polarization of M2-like TAMs via the PI3K/Akt/mTOR signaling pathway. | Jang, Hyeonha; Ojha, Uttam; Jeong, Ji-Hak; Park, Keun-Gyu; Lee, Shin Yup; Lee, You Mie | Kyungpook Natl Univ, Coll Pharm, Vessel Organ Interact Res Ctr VOICE, MRC, Daegu 41566, South Korea; Kyungpook Natl Univ, Res Inst Pharmaceut Sci, Daegu 41566, South Korea; Kyungpook Natl Univ, Coll Pharm, Daegu 41566, South Korea; Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Internal Med, Daegu 41944, South Korea | ; Lee, Kyung-Soo/C-9016-2011 | 57218761651; 57192203609; 55913671500; 57202558343; 49863712700; 8230508600 | lym@knu.ac.kr; | ARCHIVES OF PHARMACAL RESEARCH | ARCH PHARM RES | 0253-6269 | 1976-3786 | 46 | 7 | SCIE | CHEMISTRY, MEDICINAL;PHARMACOLOGY & PHARMACY | 2023 | 6.9 | 3.5 | 0.94 | 2025-06-25 | 6 | 7 | Angiogenesis; Myriocin; Tumor-associated macrophages; Tumor microenvironment | SERINE PALMITOYLTRANSFERASE INHIBITOR; LUNG-CANCER; ACTIVATION; DIFFERENTIATION; EXPRESSION | Angiogenesis; Myriocin; Tumor microenvironment; Tumor-associated macrophages | Animals; Cell Line, Tumor; Macrophages; Mice; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases; Tumor Microenvironment; Vascular Endothelial Growth Factor A; cisplatin; cytokine; gefitinib; isoflurane; luciferin; phosphatidylinositol 3 kinase; protein kinase B; thermozymocidin; vasculotropin; phosphatidylinositol 3 kinase; protein kinase B; target of rapamycin kinase; thermozymocidin; vasculotropin A; adult; Akt signaling; allograft; animal cell; animal experiment; animal model; animal tissue; Article; cancer inhibition; cancer tissue; cell differentiation; cell membrane permeability; cell population; controlled study; drug effect; drug mechanism; drug potentiation; endothelium cell; in vitro study; in vivo study; lung cancer; M1 macrophage; M2 macrophage; male; monocyte; mouse; nonhuman; polarization; protein expression; protein secretion; survival rate; synergistic effect; tumor microenvironment; tumor model; tumor vascularization; tumor-associated macrophage; animal; macrophage; metabolism; tumor cell line | English | 2023 | 2023-07 | 10.1007/s12272-023-01454-1 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | Performance Comparison of Bias-Corrected Satellite Precipitation Products by Various Deep Learning Schemes | Precipitation observations from a ground-based gauge provide a reliable data source for hydrological and climatological studies. However, these data are sparse in many regions of the world, particularly the Mekong River Basin (MRB). Satellite-based precipitation products (SPPs) are the sole data source available with worldwide coverage. Despite this, there is a mismatch between SPPs and gauge-based observations, and the correct procedures should be utilized to minimize systematic bias in SPPs. This study aimed to benchmark the efficacy of four state-of-the-art bias-correcting deep learning models (DLMs) for the tropical rainfall measuring mission-based precipitation product named TRMM₃B₄₂ (hereafter TRMM) over the entire MRB. These models were designed mainly based on convolutional neural network (CNN) and encoder-decoder (ENDE) architectures, including ConvENDE, ConvUNET, ConvINCE, and ConvLSTM. The bias-corrected dataset by DLMs was then confirmed against the gauge-based dataset (Asian precipitation-highly resolved observational data integration toward evaluation of water resources, APHRODITE). From the results obtained, all four DLMs effectively minimized the bias of the TRMM product. Among them, ConvENDE and ConvUNET had a higher consistency and performance level compared to ConvINCE and ConvLSTM. Additionally, the complexity of DLMs did not enhance their efficiency, as is the case with ConvINCE and ConvLSTM, despite using many computing resources. Given the observed data shortage for the MRB since 2016, the application of DLMs, such as ConvENDE and ConvUNET, can serve to improve the reliability of existing rainfall datasets and provide valuable input for various research purposes in the MRB. | Le, Xuan-Hien; Nguyen, Duc Hai; Lee, Giha | Kyungpook Natl Univ, Dept Adv Sci & Technol Convergence, Sangju 37224, South Korea; Thuyloi Univ, Fac Water Resources Engn, Hanoi 10000, Vietnam | Nguyen, Hai/AAD-8210-2020; Le, Xuan-Hien/AAZ-9166-2021 | 57209735659; 57215097506; 35069799400 | hienlx@knu.ac.kr;haind@tlu.edu.vn;leegiha@knu.ac.kr; | IEEE TRANSACTIONS ON GEOSCIENCE AND REMOTE SENSING | IEEE T GEOSCI REMOTE | 0196-2892 | 1558-0644 | 61 | SCIE | ENGINEERING, ELECTRICAL & ELECTRONIC;GEOCHEMISTRY & GEOPHYSICS;IMAGING SCIENCE & PHOTOGRAPHIC TECHNOLOGY;REMOTE SENSING | 2023 | 7.5 | 3.5 | 0.82 | 2025-06-25 | 4 | 6 | Precipitation; Water resources; Satellites; Monsoons; Asia; Spatial resolution; Rivers; Bias correction; deep learning; Mekong River; satellite precipitation; tropical rainfall measuring mission (TRMM) | RIVER; RAINFALL; TMPA; NETWORK; IMPACT | Bias correction; deep learning; Mekong River; satellite precipitation; tropical rainfall measuring mission (TRMM) | Mekong River; Data integration; Deep learning; Neural networks; Rain; Rain gages; Satellites; Asia; Bias correction; Deep learning; Learning models; Mekong River; Monsoon; Satellite precipitation; Spatial resolution; TRMM; Waters resources; comparative study; correction; design; machine learning; performance assessment; precipitation (climatology); sampling bias; satellite data; TRMM; Rivers | English | 2023 | 2023 | 10.1109/tgrs.2023.3299234 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Article | Psychiatric Comorbidities and Schizophrenia in Youths With Attention-Deficit/Hyperactivity Disorder | IMPORTANCE The association between attention-deficit/hyperactivity disorder (ADHD) and schizophrenia has received increased attention; however, evidence on the association between psychiatric comorbidities and subsequent schizophrenia in patients with ADHD is limited.OBJECTIVE To investigate the risk of being diagnosed with schizophrenia in children and adolescents with ADHD considering the presence of psychiatric comorbidity.DESIGN, SETTING, AND PARTICIPANTS This was a population-based, retrospective cohort study using the Health Insurance Review and Assessment claims database from January 1, 2007, to December 31, 2019. Participants were children and adolescents aged 5 to 19 years who received an ADHD diagnosis between January 1, 2010, and December 31, 2018, in the nationwide claims data of Korea. Data were analyzed from January 2010 to December 2019.INTERVENTIONS OR EXPOSURES The presence of psychiatric comorbidity was assessed from diagnosis records within 1 year before ADHD diagnosis. Comorbidities were further categorized according to the number of comorbidities and specific comorbid disorders.MAIN OUTCOMES AND MEASURES Cox proportional hazard models were used to estimate hazard ratios (HRs) and 95% CIs, examining the association between psychiatric comorbidities and the risk of being diagnosed with schizophrenia. Furthermore, the occurrence of psychiatric comorbidity during the follow-up period was explored among patients without psychiatric comorbidity at baseline.RESULTS A total of 211705 patients with newly diagnosed ADHD were included. A total of 157 272 patients (74.3%) were male, and the age of 5 to 9 years showed the highest distribution (115 081 patients [54.4%]). Patients with psychiatric comorbidity had a significantly higher risk of being diagnosed with schizophrenia than those without (adjusted HR, 2.14; 95% CI, 2.05-2.23). The association between schizophrenia and psychiatric comorbidity became progressively greater with the increasing number of comorbidities. Several individual psychiatric disorders showed an association with development of schizophrenia, with ASD, intellectual disability, tic disorder, depression, and bipolar disorder being the top 5 disorders most associated. Furthermore, 3244 patients (73.8%) without psychiatric comorbidities experienced the emergence of other psychiatric disorders before schizophrenia occurrence.CONCLUSIONS AND RELEVANCE In this retrospective cohort study involving children and adolescents with ADHD, the presence of psychiatric comorbidity in patients with ADHD was associated with an increased risk of being diagnosed with schizophrenia, with an increased risk observed in multiple comorbidities and a wide variety of comorbidities. These findings highlight the significance of assessing and managing psychiatric comorbidities in patients with ADHD to decrease subsequent schizophrenia risk and allow for early intervention. | Jeon, Soo Min; Lee, Dong Yun; Cha, Sanghun; Kwon, Jin-Won | Jeju Natl Univ, Coll Pharm, Jeju, South Korea; Ajou Univ, Sch Med, Dept Biomed Informat, Suwon, South Korea; Kyungpook Natl Univ, Coll Nat Sci, Dept Stat, Daegu, South Korea; Kyungpook Natl Univ, Coll Pharm, BK21 FOUR Community Based Intelligent Novel Drug D, Daegu, South Korea; Kyungpook Natl Univ, Res Inst Pharmaceut Sci, 80 Daehak Ro, Daegu 41566, South Korea; Kyungpook Natl Univ, Coll Pharm, 80 Daehak Ro, Daegu 41566, South Korea | lee, dong/I-9385-2017 | 57206855645; 57211471101; 57638252600; 16202951700 | jwkwon@knu.ac.kr; | JAMA NETWORK OPEN | JAMA NETW OPEN | 2574-3805 | 6 | 11 | SCIE | MEDICINE, GENERAL & INTERNAL | 2023 | 10.5 | 3.5 | 1.28 | 2025-06-25 | 5 | 5 | DEFICIT HYPERACTIVITY DISORDER; BIPOLAR DISORDER; PSYCHOTIC DISORDER; RISK; ADULTS; ADHD; DEPRESSION; RECOVERY; SYMPTOMS; BIRTH | Adolescent; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Child; Comorbidity; Female; Humans; Male; Retrospective Studies; Schizophrenia; Article; attention deficit hyperactivity disorder; autism; bipolar disorder; child; cohort analysis; comorbidity; depression; female; follow up; health insurance; human; intellectual impairment; major clinical study; male; mental disease; retrospective study; schizophrenia; adolescent; attention deficit hyperactivity disorder; bipolar disorder; comorbidity; schizophrenia | English | 2023 | 2023-11-30 | 10.1001/jamanetworkopen.2023.45793 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||||
| ○ | ○ | Article | Rate-Splitting Multiple Access for Downlink MIMO: A Generalized Power Iteration Approach | Rate-splitting multiple access (RSMA) is a general multiple access scheme for downlink multi-antenna systems embracing both classical spatial division multiple access and more recent non-orthogonal multiple access. Finding a linear precoding strategy that maximizes the sum spectral efficiency of RSMA is a challenging yet significant problem. In this paper, we put forth a novel precoder design framework that jointly finds the linear precoders for the common and private messages for RSMA. Our approach is first to approximate the non-smooth minimum function part in the sum spectral efficiency of RSMA using a LogSumExp technique. Then, we reformulate the sum spectral efficiency maximization problem as a form of the log-sum of Rayleigh quotients to convert it into a tractable form. By interpreting the first-order optimality condition of the reformulated problem as an eigenvector-dependent nonlinear eigenvalue problem, we reveal that the leading eigenvector of the derived optimality condition is a local optimal solution. To find the leading eigenvector, we propose an algorithm inspired by a power iteration. Simulation results show that the proposed RSMA transmission strategy provides significant improvement in the sum spectral efficiency compared to the state-of-the-art RSMA transmission methods. | Park, Jeonghun; Choi, Jinseok; Lee, Namyoon; Shin, Wonjae; Poor, H. Vincent | Kyungpook Natl Univ, Sch Elect Engn, Daegu 41566, South Korea; Ulsan Natl Inst Sci & Technol, Dept Elect Engn, Ulsan 44919, South Korea; Korea Univ, Sch Elect Engn, Seoul 02841, South Korea; Ajou Univ, Dept Elect & Comp Engn, Suwon 16499, South Korea; Princeton Univ, Dept Elect & Comp Engn, Princeton, NJ 08544 USA | ; Lee, Namyoon/ADH-9232-2022; Choi, Jinseok/AAL-6383-2020; Poor, H./S-5027-2016 | 57853652900; 57190581671; 35148128800; 36009462000; 55665272100 | jeonghun.park@knu.ac.kr;jinseokchoi@unist.ac.kr;amyoon@korea.ac.kr;wjshin@ajou.ac.kr;poor@princeton.edu; | IEEE TRANSACTIONS ON WIRELESS COMMUNICATIONS | IEEE T WIREL COMMUN | 1536-1276 | 1558-2248 | 22 | 3 | SCIE | ENGINEERING, ELECTRICAL & ELECTRONIC;TELECOMMUNICATIONS | 2023 | 8.9 | 3.5 | 4.35 | 2025-06-25 | 22 | 31 | Downlink; Precoding; Transmitters; MIMO communication; Optimization; Multiaccess communication; Channel estimation; Rate-splitting multiple access (RSMA); multi-user MIMO; imperfect channel state information (CSI); sum spectral efficiency maximization; generalized power iteration | MULTIUSER MISO SYSTEMS; SUM-RATE MAXIMIZATION; BROADCAST CHANNEL; SPECTRAL EFFICIENCY; IMPERFECT CSIT; DESIGN; TRANSMISSION; NETWORKS; STRATEGY | generalized power iteration; imperfect channel state information (CSI); multi-user MIMO; Rate-splitting multiple access (RSMA); sum spectral efficiency maximization | Antennas; Channel estimation; Channel state information; Communication channels (information theory); Iterative methods; MIMO systems; Spectrum efficiency; Downlink; Generalized power iteration; Imperfect channel state information; MIMO communication; Multi-user MIMO; Multiaccess communication; Multiple access; Optimisations; Power; Precoding; Rate splitting; Rate-splitting multiple access; Spectral efficiency maximizations; Sum spectral efficiency maximization; Eigenvalues and eigenfunctions | English | 2023 | 2023-03 | 10.1109/twc.2022.3205480 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | Reconfigurable dual-mode optical encryption enabled by block copolymer photonic crystal with micro-imprinted holographic metasurface | Dual-mode optical encryption based on holographic metasurfaces and color components is of great attraction because of their enhanced information security and storage; however, the realization of independently as well as reversibly encodable holographic metasurfaces and color components remains unreported. Herein, we present reconfigurable dual-mode encryptions of structural colors (SC) and holograms, achieved through stimuli-responsive block copolymer (BCP) photonic crystals (PCs) with micro-imprinted holographic metasurfaces. Holographic images appear when the micro-imprinted BCP PCs, consisting of self-assembled alternating lamellae of two dielectrics, are exposed to an incident laser. A characteristic SC develops in the visible range when the imprinted film is immersed in a liquid agent that can swell one of the dielectrics, allowing for dual-mode holographic and SC encodings in the solid and liquid states, respectively. The dual-mode optical encoding is reconfigured. The holographic image can be erased and replaced with another micropattern, while preserving the SC. Moreover, an SC, set by crosslinking of the swellable lamellae, is reset by chemical de-crosslinking and subsequent transient re-crosslinking, enabling the SC reconfigurability of the BCP PC film. A prototype of a high-security reconfigurable dual encryption has been developed, wherein true information is decrypted when holographic passwords are confirmed with full-color visible SC passwords. | Mun, Seungsoo; Park, Tae Hyun; Oh, Jin Woo; Kim, Taebin; Lee, Kyuho; Lee, Chang Eun; Kim, Hoyeon; Park, Jong Woong; Jeon, Seungbae; Ryu, Du Yeol; Cheon, Sanghoon; Kim, Yong-Hae; Lee, Seung-Yeol; Hwang, Chi-Sun; Kim, Joo Yeon; Park, Cheolmin | Yonsei Univ, Dept Mat Sci & Engn, Yonsei Ro 50, Seoul 03722, South Korea; Linkoping Univ, Dept Sci & Technol, Lab Organ Elect, S-60174 Norrkoping, Sweden; Yonsei Univ, Dept Chem & Biomol Engn, Seoul 120749, South Korea; Elect & Telecommun Res Inst ETRI, Real Device Res Div, Real Display Res Lab, Daejeon 34129, South Korea; Kyungpook Natl Univ, Sch Elect & Elect Engn, Daehak Ro 80, Daegu, South Korea | Kim, Yong-Joo/AAK-1840-2021 | 57222064295; 57317526200; 58831072400; 57221093416; 55737427600; 57220182596; 57354608300; 16643712800; 57203852858; 7103143784; 7006424837; 7410208969; 55881869300; 57206755224; 26663174900; 56488841400 | jooyeon.kim@etri.re.kr;cmpark@yonsei.ac.kr; | MATERIALS TODAY | MATER TODAY | 1369-7021 | 1873-4103 | 70 | SCIE | MATERIALS SCIENCE, MULTIDISCIPLINARY | 2023 | 21.1 | 3.5 | 0.98 | 2025-06-25 | 8 | 8 | Reconfigurable dual-mode encryption; Self-assembled photonic crystals; Block copolymer structural colors; Micro-imprinted holographic metasurfaces; High-security information encryption | COLOR PRINTS; SECURITY; POLYMER; SINGLE; GELS | Block copolymer structural colors; High-security information encryption; Micro-imprinted holographic metasurfaces; Reconfigurable dual-mode encryption; Self-assembled photonic crystals | Authentication; Color; Crosslinking; Cryptography; Encoding (symbols); Holograms; Liquid crystals; Microcomputers; Photonic crystals; Block co polymers; Block copolymer structural color; Dual modes; High securities; High-security information encryption; Metasurface; Micro-imprinted holographic metasurface; Reconfigurable; Reconfigurable dual-mode encryption; Self assembled photonic crystals; Structural color; Block copolymers | English | 2023 | 2023-11 | 10.1016/j.mattod.2023.10.006 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Article | Relative Importance of Radar Variables for Nowcasting Heavy Rainfall: A Machine Learning Approach | Highly short-term forecasting, or nowcasting, of heavy rainfall due to rapidly evolving mesoscale convective systems (MCSs) is particularly challenging for traditional numerical weather prediction (NWP) models. To overcome such a challenge, a growing number of studies have shown significant advantages of using machine learning (ML) modeling techniques with remote sensing data, especially weather radar data, for high-resolution rainfall nowcasting. To improve ML model performance, it is essential first and foremost to quantify the importance of radar variables and identify pertinent predictors of rainfall that can also be associated with domain knowledge. In this study, a set of MCS types consisting of convective cell (CC), mesoscale CC, diagonal squall line (SLD), and parallel squall line (SLP), was adopted to categorize MCS storm cells, following the fuzzy logic algorithm for storm tracking (FAST), over the Korean Peninsula. The relationships between rain rates and over 15 variables derived from data products of dual-polarimetric weather radar were investigated and quantified via five ML regression methods and a permutation importance algorithm. As an applicational example, ML classification models were also developed to predict locations of storm cells. Recalibrated ML regression models with identified pertinent predictors were coupled with the ML classification models to provide early warnings of heavy rainfall. Results imply that future work needs to consider MCS type information to improve ML modeling for nowcasting and early warning of heavy rainfall. | Wang, Yi Victor; Kim, Seung Hee; Lyu, Geunsu; Lee, Choeng-Lyong; Lee, Gyuwon; Min, Ki-Hong; Kafatos, Menas C. | Chapman Univ, Inst Earth Comp Human & Observing, Orange, CA 92866 USA; Kyungpook Natl Univ, Ctr Atmospher Remote Sensing CARE, Daegu, South Korea; Kyungpook Natl Univ, Dept Astron & Atmospher Sci, Daegu, South Korea | Wang, Yi/AAJ-9538-2020 | 57213272530; 57206876105; 57204505581; 58064034000; 7404852271; 37089364100; 7003811919 | ywang2@chapman.edu;sekim@chapman.edu;geunsulyu@gmail.com;lchly747@naver.com;gyuwon@knu.ac.kr;kmin@knu.ac.kr;kafatos@chapman.edu; | IEEE TRANSACTIONS ON GEOSCIENCE AND REMOTE SENSING | IEEE T GEOSCI REMOTE | 0196-2892 | 1558-0644 | 61 | SCIE | ENGINEERING, ELECTRICAL & ELECTRONIC;GEOCHEMISTRY & GEOPHYSICS;IMAGING SCIENCE & PHOTOGRAPHIC TECHNOLOGY;REMOTE SENSING | 2023 | 7.5 | 3.5 | 1.23 | 2025-06-25 | 9 | 9 | Artificial neural network (ANN); convolutional neural network (CNN); deep learning; dual-polarimetric weather radar; early warning; flash flood; hydrometeorological hazard; Lasso; mesoscale convective system (MCS); permutation impor-tance; random forest; remote sensing; storm; support vector regression (SVR) | PRECIPITATION; TRACKING; IDENTIFICATION; SYSTEMS | Artificial neural network (ANN); convolutional neural network (CNN); deep learning; dual-polarimetric weather radar; early warning; flash flood; hydrometeorological hazard; Lasso; mesoscale convective system (MCS); permutation importance; random forest; remote sensing; storm; support vector regression (SVR) | Korea; Cells; Cytology; Deep neural networks; Forestry; Fuzzy logic; Meteorological radar; Multilayer neural networks; Polarimeters; Rain gages; Regression analysis; Remote sensing; Storms; Weather forecasting; Convolutional neural network; Deep learning; Dual-polarimetric weather radar; Early warning; Flash-floods; Hydrometeorological hazard; Input variables; Lasso; Mesoscale Convective System; Permutation importance; Predictive models; Random forests; Remote-sensing; Support vector regressions; algorithm; artificial neural network; early warning system; hydrometeorology; machine learning; nowcasting; radar; rainfall; remote sensing; satellite data; storm; support vector machine; weather forecasting; Rain | English | 2023 | 2023 | 10.1109/tgrs.2022.3231125 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | Meeting Abstract | Relevance of cough in patients with severe asthma: Analysis from the Korean Severe Asthma Registry (KoSAR) study | Lee, Hwa Young; Lee, Youngsoo; Lee, Seung-Eun; Sim, Da Woon; Kang, Noeul; Lee, Byung-Jae; Kim, Joo-Hee; Kang, Sung-Yoon; Ban, Ga-Young; Nam, Young Hee; Kim, Sujeong; Park, Chan Sun; Kim, So Ri; An, Jin; Kim, Byung Keun; Park, Heung-Woo; Lee, Taehoon; Lee, Ji-Ho; Park, So-Young; Lee, Sook Young; Park, Hae-Sim; Cho, You Sook; Kim, Sang-Heon; Song, Woo-Jung | Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Internal Med,Div Allergy, Seoul, South Korea; Ajou Univ, Sch Med, Dept Allergy & Clin Immunol, Suwon, South Korea; Pusan Natl Univ, Yangsan Hosp, Dept Internal Med, Yangsan, South Korea; Chonnam Natl Univ, Chonnam Natl Univ Hosp, Med Sch, Dept Allergy & Clin Immunol, Gwangju, South Korea; Sungkyunkwan Univ, Coll Med, Samsung Med Ctr, Dept Med,Div Allergy, Seoul, South Korea; Hallym Univ, Coll Med, Dept Internal Med, Anyang, South Korea; Gachon Univ, Gil Med Ctr, Dept Internal Med, Incheon, South Korea; Hallym Univ, Kangdong Sacred Heart Hosp, Coll Med, Dept Pulm Allergy & Crit Care Med, Seoul, South Korea; Dong A Univ, Coll Med, Dept Internal Med, Busan, South Korea; Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea; Inje Univ, Haeundae Paik Hosp, Dept Internal Med, Busan, South Korea; Chonbuk Natl Univ, Med Sch, Dept Internal Med, Div Resp Med & Allergy, Jeonju, South Korea; Kyung Hee Univ, Kyung Hee Univ Hosp Gangdong, Coll Med, Dept Pulm Allergy & Crit Care Med, Seoul, South Korea; Korea Univ, Coll Med, Dept Internal Med, Div Pulmonol Allergy & Crit Care Med, Seoul, South Korea; Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul, South Korea; Univ Ulsan, Ulsan Univ Hosp, Coll Med, Dept Internal Med,Div Pulm & Crit Care Med, Ulsan, South Korea; Yonsei Univ, Wonju Coll Med, Dept Internal Med, Wonju, South Korea; Chung Ang Univ, Coll Med, Dept Internal Med, Gwangmyeong, South Korea; Univ Ulsan, Coll Med, Asan Med Ctr, Dept Allergy & Clin Immunol, Seoul, South Korea; Hanyang Univ, Coll Med, Dept Internal Med, Div Pulm Med & Allergy, Seoul, South Korea | Kim, So/AAS-1630-2021; Ban, Ga-Young/AFT-6303-2022; Kim, Byung-Keun/N-4256-2018; Kang, Sung-Yoon/AAG-7523-2020; Lee, Jeong/JFA-4725-2023; Kim, Ju-Hyoung/N-1450-2019 | lehwyo@catholic.ac.kr; | EUROPEAN RESPIRATORY JOURNAL | EUR RESPIR J | 0903-1936 | 1399-3003 | 62 | SCIE | RESPIRATORY SYSTEM | 2023 | 17 | 3.5 | 0 | English | 2023 | 2023-09-09 | 10.1183/13993003.congress-2023.pa3034 | 바로가기 | 바로가기 | 바로가기 | |||||||||||||
| ○ | ○ | Article | Steppogenin suppresses tumor growth and sprouting angiogenesis through inhibition of HIF-1α in tumors and DLL4 activity in the endothelium | Background: Hypoxia is a characteristic feature of many solid tumors. As an adaptive response to hypoxia, tumor cells activate hypoxia-inducible factor-1 alpha (HIF-1 alpha). Under hypoxic conditions, angiogenesis mediated by HIF-1 alpha is involved in the growth and metastasis of tumor cells. During the angiogenic process, differentiated tip endothelial cells (ECs) characterized by high expression of DLL4 promote angiogenic germination through filopodia. Inhibitors of HIF-1 alpha or DLL4 have been widely studied Purpose: We tried to find inhibitors targeting both HIF-1 alpha and DLL4 in tumor which have not yet been developed. Study design: In this study, we examined a natural compound that inhibits sprouting angiogenesis and tumor growth by targeting both HIF-1 alpha and DLL4 under hypoxic conditions. Methods: After examining cell viability of 70 selected natural compounds, we assessed the effects of compounds on HIF-1 alpha and DLL4 transcriptional activity using a dual-luciferase reporter assay. Western blot analysis, immunofluoresecnt assay and real-time qPCR were performed to identify expression of proteins, such as HIF-1 alpha and DLL4, as well as HIF-1 alpha target genes under hypoxic conditions. In vitro angiogenesis assay and in vivo allograft tumor experiment were performed to investigate inhibition of tumor growth through anti-angiogenic activity. Results: Among these compounds, steppogenin, which is extracted from the root bark of Morus alba l, respectively inhibited the transcriptional activity of HIF-1 alpha under hypoxic conditions in HEK293T cells and vascular endo-thelial growth factor (VEGF)-induced DLL4 expression in vascular ECs in a dose-dependent manner. In tumor cells and retinal pigment epithelial cells, steppogenin significantly suppressed HIF-1 alpha protein levels under hypoxic conditions as well as VEGF-induced DLL4 expression in ECs. Furthermore, steppogenin suppressed hypoxia-induced vascular EC proliferation and migration as well as VEGF-induced sprouting of EC spheroids. Conclusion: These results suggest that the natural compound steppogenin could potentially be used to treat angiogenic diseases, such as those involving solid tumors, because of its dual inhibition of HIF-1 alpha and DLL4. | Cha, Sora; Kim, Hyoung-Geun; Jang, Hyeonha; Lee, Jihoon; Chao, Tang; Baek, Nam-In; Song, Im-Sook; Lee, You Mie | Kyungpook Natl Univ, Coll Pharm, Vessel Organ Interact Res Ctr, VOICE MRC, 80 Daehak Ro, Daegu 41566, South Korea; Kyungpook Natl Univ, Coll Pharm, BK21 FOUR Community Based Intelligent Novel Drug D, Daegu 41566, South Korea; Kyungpook Natl Univ, Res Inst Pharmaceut Sci, Daegu 41566, South Korea; Kyung Hee Univ, Grad Sch Biotechnol, Yongin 17104, South Korea; Kyung Hee Univ, Dept Oriental Med Biotechnol, Yongin 17104, South Korea | Lee, Kyung-Soo/C-9016-2011; Baek, Nam-In/AAK-7447-2020; Tang, Chao/HRB-9640-2023 | 57948645300; 57192300072; 57218761651; 57195979045; 57949259900; 57214954753; 7201564500; 8230508600 | lym@knu.ac.kr; | PHYTOMEDICINE | PHYTOMEDICINE | 0944-7113 | 1618-095X | 108 | SCIE | CHEMISTRY, MEDICINAL;INTEGRATIVE & COMPLEMENTARY MEDICINE;PHARMACOLOGY & PHARMACY;PLANT SCIENCES | 2023 | 6.7 | 3.5 | 1.73 | 2025-06-25 | 9 | 9 | Steppogenin; Hypoxia; HIF-1? DLL4; Angiogenesis; Solid tumor | HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; CANCER-CELLS; METASTASIS; EXPRESSION; BLOCKADE; HIF-1; HEAD | Angiogenesis; HIF-1α, DLL4; Hypoxia; Solid tumor; Steppogenin | Adaptor Proteins, Signal Transducing; Calcium-Binding Proteins; Cell Hypoxia; Cell Line, Tumor; Endothelial Cells; Endothelium; HEK293 Cells; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Neoplasms; Neovascularization, Pathologic; Vascular Endothelial Growth Factor A; antineoplastic agent; delta like protein 4; dimethyl sulfoxide; glucose; herbaceous agent; hypoxia inducible factor 1alpha; messenger RNA; naringenin; Notch receptor; pimonidazole; steppogenin; tanespimycin; unclassified drug; vasculotropin; calcium binding protein; DLL4 protein, human; hypoxia inducible factor 1alpha; signal transducing adaptor protein; vasculotropin A; adult; allograft; angiogenesis assay; animal experiment; animal model; animal tissue; antiangiogenic activity; antineoplastic activity; area under the curve; Article; bark; brain tissue; cancer inhibition; cell migration; cell proliferation; cell survival; cell viability; controlled study; cytotoxicity assay; drug tissue level; EA.hy 926 cell line; endothelium; gene expression regulation; glucose metabolism; heart tissue; HEK293T cell line; human; human cell; HUVEC cell line; IC50; immunofluorescence; immunofluorescence assay; immunohistochemistry; in vitro study; in vivo study; inoculation; ionization; kidney tissue; Lewis lung carcinoma cell line; liver tissue; luciferase assay; lung parenchyma; male; maximum concentration; metastasis; Morus alba; mouse; mRNA expression level; nonhuman; plant root; protein expression; real time polymerase chain reaction; real time reverse transcription polymerase chain reaction; retinal pigment epithelium; RNA isolation; spleen tissue; sprouting angiogenesis; time to maximum plasma concentration; tissue distribution; tissue homogenate; transactivation; tumor cell; tumor hypoxia; tumor spheroid; tumor volume; Western blotting; cell hypoxia; endothelium cell; HEK293 cell line; hypoxia; metabolism; neoplasm; neovascularization (pathology); pathology; tumor cell line | English | 2023 | 2023-01 | 10.1016/j.phymed.2022.154513 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Article | Survival Outcomes in Premenopausal Patients With Invasive Lobular Carcinoma | IMPORTANCE The disparate prognostic implications between invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) have been demonstrated. However, information on premenopausal patients remains insufficient. OBJECTIVE To examine long-term survival outcomes of ILC and IDC in premenopausal patients using national databases. DESIGN, SETTING, AND PARTICIPANTS This cohort study used the Surveillance, Epidemiology, and End Results (SEER), Korean Breast Cancer Registry (KBCR), and Asan Medical Center Research (AMCR) databases to identify premenopausal patients with stage I to III ILC or IDC between January 1, 1990, and December 31, 2015. The median follow-up time was 90 (IQR, 40-151) months in the SEER database, 94 (IQR, 65-131) months in the KBCR database, and 120 (IQR, 86-164) months in the AMCR database. Data were analyzed from January 1 to May 31, 2023. MAIN OUTCOMES AND MEASURES The primary outcome was breast cancer-specific survival (BCSS), which was analyzed according to histological type, and the annual hazard rate was evaluated. Survival rates were analyzed using a log-rank test and a Cox proportional hazards regression model with time-varying coefficients. Multivariable analysis was performed by adjusting for tumor characteristics and treatment factors. RESULTS A total of 225 938 women diagnosed with IDC or ILC and younger than 50 years were identified. Mean (SD) age at diagnosis was 42.7 (5.3) years in the SEER database, 41.8 (5.5) years in the KBCR database, and 41.8 (5.5) years in the AMCR database. In terms of race (available for the SEER database only), 12.4% of patients were Black, 76.1% were White, 11.0% were of other race (including American Indian or Alaska Native, Asian, and Native Hawaiian or Other Pacific Islander), and 0.5% were of unknown race). Patients with ILC had better BCSS in the first 10 years after diagnosis than those with IDC (hazard ratios [HRs], 0.73 [95% CI, 0.68-0.78] in the SEER database, 1.20 [95% CI, 0.91-1.58] in the KBCR database, and 0.50 [95% CI, 0.29-0.86] in the AMCR database), although BCSS was worse after year 10 (HRs, 1.80 [95% CI, 1.59-2.02] in the SEER database, 2.79 [95% CI, 1.32-5.88] in the KBCR database, and 2.23 [95% CI, 1.04-4.79] in the AMCR database). Similar trends were observed for hormone receptor-positive tumors (HRs, 1.55 [95% CI, 1.37-1.75] in the SEER database, 2.27 [95% CI, 1.01-5.10] in the KBCR database, and 2.12 [95% CI, 0.98-4.60] in the AMCR database). Considering the annual hazard model of BCSS, IDC events tended to decline steadily after peaking 5 years before diagnosis. However, the annual peak event of BCSS was observed 5 years after diagnosis for ILC, which subsequently remained constant. CONCLUSIONS AND RELEVANCE These findings suggest that premenopausal women with ILC have worse BCSS estimates than those with IDC, which can be attributed to a higher late recurrence rate of ILC than that of IDC. Histological subtypes should be considered when determining the type and duration of endocrine therapy in premenopausal women. | Yoon, Tae In; Jeong, Joon; Lee, Seokwon; Ryu, Jai Min; Lee, Young Joo; Lee, Jee Yeon; Hwang, Ki-Tae; Kim, Hakyoung; Kim, Seonok; Lee, Sae Byul; Ko, Beom Seok; Lee, JongWon; Son, Byung Ho; Metzger, Otto; Kim, Hee Jeong | Dongnam Inst Radiol & Med Sci, Dept Surg, Div Breast Surg, Busan, South Korea; Yonsei Univ, Gangnam Severance Hosp, Dept Surg, Seoul, South Korea; Pusan Natl Univ, Pusan Natl Univ Hosp, Biomed Res Inst, Sch Med,Dept Surg, Busan, South Korea; Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Dept Surg,Div Breast Surg, Seoul, South Korea; Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Surg,Div Breast Surg, Seoul, South Korea; Kyungpook Natl Univ, Chilgok Hosp, Sch Med, Dept Surg, Daegu, South Korea; Seoul Natl Univ, Seoul Metropolitan Govt, Boramae Med Ctr, Coll Med,Dept Surg, Seoul, South Korea; Dongguk Univ, Ilsan Hosp, Coll Med, Dept Surg, Goyang, South Korea; Univ Ulsan, Coll Med, Dept Clin Epidemiol & Biostat, Asan Med Ctr, Seoul, South Korea; Univ Ulsan, Coll Med, Dept Surg, Asan Med Ctr,Div Breast, Seoul, South Korea; Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA | Park, Joonhong/AAZ-9885-2020; Lee, Jong-Mok/KVY-9550-2024 | 57104434600; 55184774900; 55555956700; 57158270000; 58019185800; 37079213100; 57197884861; 56606776100; 57196230629; 56556623100; 56781006300; 55992285000; 26028949200; 30267803500; 14626479600 | haapybirth@amc.seoul.kr; | JAMA NETWORK OPEN | JAMA NETW OPEN | 2574-3805 | 6 | 11 | SCIE | MEDICINE, GENERAL & INTERNAL | 2023 | 10.5 | 3.5 | 2.05 | 2025-06-25 | 8 | 8 | NEOADJUVANT CHEMOTHERAPY; DUCTAL CARCINOMA; BREAST-CANCER; LONG-TERM; STAGE-I; THERAPY; BENEFIT; TAMOXIFEN | Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cohort Studies; Female; Humans; Prognosis; antineoplastic agent; adjuvant chemotherapy; adult; Article; breast cancer; cancer hormone therapy; cancer registry; cancer survival; cohort analysis; controlled study; female; follow up; gastrointestinal tract; hormonal therapy; human; invasive lobular breast carcinoma; long term survival; major clinical study; premenopause; proportional hazards model; statistical significance; surgeon; breast ductal carcinoma; breast tumor; lobular carcinoma; prognosis | English | 2023 | 2023-11-08 | 10.1001/jamanetworkopen.2023.42270 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||||
| ○ | ○ | Review | Tumor lactic acid: a potential target for cancer therapy | Tumor development is influenced by circulating metabolites and most tumors are exposed to substantially elevated levels of lactic acid and low levels of nutrients, such as glucose and glutamine. Tumor-derived lactic acid, the major circulating carbon metabolite, regulates energy metabolism and cancer cell signaling pathways, while also acting as an energy source and signaling molecule. Recent studies have yielded new insights into the pro-tumorigenic action of lactic acid and its metabolism. These insights suggest an anti-tumor therapeutic strategy targeting the oncometabolite lactic acid, with the aim of improving the efficacy and clinical safety of tumor metabolism inhibitors. This review describes the current understanding of the multifunctional roles of tumor lactic acid, as well as therapeutic approaches targeting lactic acid metabolism, including lactate dehydrogenase and monocarboxylate transporters, for anti-cancer therapy. | Byun, Jun-Kyu | Kyungpook Natl Univ, Res Inst Pharmaceut Sci, Coll Pharm, BK21 FOUR Community Based Intelligent Novel Drug D, 80 Daehak Ro, Daegu 41566, South Korea | 57190427423 | jkbyun@knu.ac.kr; | ARCHIVES OF PHARMACAL RESEARCH | ARCH PHARM RES | 0253-6269 | 1976-3786 | 46 | 2 | SCIE | CHEMISTRY, MEDICINAL;PHARMACOLOGY & PHARMACY | 2023 | 6.9 | 3.5 | 1.39 | 2025-06-25 | 22 | 22 | Tumors; Lactic acid; Lactate dehydrogenases; Monocarboxylate transporters; Lactic acid blocking strategy; Anti-tumor therapy | MONOCARBOXYLATE TRANSPORTER 1; LACTATE-DEHYDROGENASE-B; SUPPRESSOR-CELLS; METABOLIC HETEROGENEITY; AEROBIC GLYCOLYSIS; STRUCTURAL BASIS; LUNG-CANCER; H SUBUNIT; INHIBITION; GROWTH | Anti-tumor therapy; Lactate dehydrogenases; Lactic acid; Lactic acid blocking strategy; Monocarboxylate transporters; Tumors | Energy Metabolism; Humans; Lactic Acid; Neoplasms; Signal Transduction; antineoplastic agent; arginase 1; azd 3965; bay 8022; galloflavin; glucose; glutamine; gne 140; histone deacetylase inhibitor; hypoxia inducible factor 1alpha; hypoxia inducible factor 2alpha; iacs 010759; immunoglobulin enhancer binding protein; lactate dehydrogenase; lactic acid; monocarboxylate transporter; monocarboxylate transporter 1; monocarboxylate transporter 2; monocarboxylate transporter 3; monocarboxylate transporter 4; nci 006; reduced nicotinamide adenine dinucleotide; unclassified drug; vasculotropin; vb 124; lactic acid; antineoplastic activity; cancer associated fibroblast; cancer therapy; CD4+ T lymphocyte; cell migration; cell proliferation; dendritic cell; glycolysis; human; macrophage; myeloid-derived suppressor cell; natural killer cell; natural killer T cell; nonhuman; organisms by electron donor; protein analysis; protein expression; protein metabolism; protein structure; protein targeting; regulatory mechanism; regulatory T lymphocyte; Review; signal transduction; T lymphocyte; tumor microenvironment; energy metabolism; metabolism; neoplasm | English | 2023 | 2023-02 | 10.1007/s12272-023-01431-8 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Article | Treatment With Liposomal Irinotecan Plus Fluorouracil and Leucovorin for Patients With Previously Treated Metastatic Biliary Tract Cancer The Phase 2b NIFTY Randomized Clinical Trial | Importance The NIFTY trial demonstrated the benefit of treatment with second-line liposomal irinotecan (nal-IRI) plus fluorouracil (FU) and leucovorin (LV) for patients with advanced biliary tract cancer (BTC).Objective To report the updated efficacy outcomes from the NIFTY trial with extended follow-up of 1.3 years with reperformed masked independent central review (MICR) with 3 newly invited radiologists.Design, Setting, and Participants The NIFTY trial was a randomized, multicenter, open-label, phase 2b clinical trial conducted between September 5, 2018, and December 31, 2021, at 5 tertiary referral centers in South Korea. Patients with advanced BTC whose disease progressed while receiving first-line gemcitabine plus cisplatin with at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors, version 1.1, were eligible. Data analysis was completed on May 9, 2022.Interventions Patients were randomized 1:1 to receive LV, 400 mg/m(2), bolus and FU, 2400 mg/m(2), for a 46-hour infusion intravenously every 2 weeks with or without nal-IRI, 70 mg/m(2), before LV intravenously. Patients were treated until disease progression or unacceptable toxic effects.Main Outcomes and Measures Primary end point was progression-free survival (PFS) as assessed by MICR. Secondary end points were PFS as assessed by the investigator, overall survival, and objective response rate.Results A total of 178 patients (75 women [42.1%]; median [IQR] age, 64 [38-84] years) were randomly assigned, and 174 patients were included in the full analysis set (88 patients [50.6%] in the nal-IRI plus FU/LV group vs 86 patients [49.4%] in the FU/LV alone group). In this updated analysis, the median MICR-assessed PFS was 4.2 months (95% CI, 2.8-5.3) for the nal-IRI plus FU/LV group and 1.7 months (95% CI, 1.4-2.6) for the FU/LV alone group (hazard ratio, 0.61; 95% CI, 0.44-0.86; P = .004), in contrast to the 7.1 and 1.4 months reported in the previous study, respectively. The discordance rate for tumor progression date between the MICR and investigators was 17.8% (vs 30% in the previous study).Conclusions and Relevance The NIFTY randomized clinical trial demonstrated significant improvement in PFS with treatment with nal-IRI plus FU/LV compared with FU/LV alone for patients with advanced BTC after progression to gemcitabine plus cisplatin. The combination of nal-IRI plus FU/LV could be considered as a second-line treatment option for patients with previously treated advanced BTC. | Hyung, Jaewon; Kim, Ilhwan; Kim, Kyu-pyo; Ryoo, Baek-Yeol; Jeong, Jae Ho; Kang, Myoung Joo; Cheon, Jaekyung; Kang, Byung Woog; Ryu, Hyewon; Lee, Ji Sung; Kim, Kyung Won; Abou-Alfa, Ghassan K.; Yoo, Changhoon | Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, 88 Olymp Ro,43 Gil, Seoul 05505, South Korea; Inje Univ, Haeundae Paik Hosp, Dept Internal Med, Div Oncol,Coll Med, Pusan, South Korea; Univ Ulsan, Ulsan Univ Hosp, Dept Internal Med, Div Hematol & Oncol,Coll Med, Ulsan, South Korea; Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Oncol Hematol, Daegu, South Korea; Chungnam Natl Univ, Chungnam Natl Univ Hosp, Dept Internal Med, Div Hematol & Oncol,Coll Med, Daejeon, South Korea; Univ Ulsan, Asan Inst Life Sci, Clin Res Ctr, Asan Med Ctr,Coll Med, Seoul, South Korea; Univ Ulsan, Asan Med Ctr, Dept Clin Epidemiol & Biostat, Coll Med, Seoul, South Korea; Univ Ulsan, Asan Inst Life Sci, Clin Res Ctr, Asan Med Ctr,Coll Med,Asan Image Metr, Seoul, South Korea; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA; Cornell Univ, Dept Med, Weill Med Coll, New York, NY USA | Kim, In-Ryoung/AGF-2385-2022; Lee, Kee-Joon/AAA-4090-2022; Kim, Hyunho/GQH-5608-2022 | 57192953911; 57202402657; 7409319176; 6603026326; 57022763500; 57190689321; 57203287161; 28567838500; 56075661600; 57217244570; 56128365800; 8660213800; 22954694200 | yooc@amc.seoul.kr; | JAMA ONCOLOGY | JAMA ONCOL | 2374-2437 | 2374-2445 | 9 | 5 | SCIE | ONCOLOGY | 2023 | 22.3 | 3.6 | 6.96 | 2025-06-25 | 46 | 46 | OPEN-LABEL; CHOLANGIOCARCINOMA; MULTICENTER; CHEMOTHERAPY; GEMCITABINE; CISPLATIN | Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liposomes; Middle Aged; Pancreatic Neoplasms; cisplatin; fluorouracil; folinic acid; gemcitabine; irinotecan; antineoplastic agent; cisplatin; doxecitine; fluorouracil; folinic acid; irinotecan; liposome; adult; aged; Article; biliary tract cancer; bone metastasis; cancer combination chemotherapy; controlled study; disease course; drug efficacy; female; human; liver metastasis; long term survival; lung metastasis; lymph node metastasis; major clinical study; male; monotherapy; multicenter study; overall survival; peritoneum metastasis; phase 2 clinical trial; post hoc analysis; progression free survival; randomized controlled trial; bile duct tumor; clinical trial; middle aged; pancreas tumor | English | 2023 | 2023-05 | 10.1001/jamaoncol.2023.0016 | 바로가기 | 바로가기 | 바로가기 | 바로가기 |
페이지 이동: